v3.26.1
License and Collaboration Arrangements (Additional Information) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2024
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Accounts receivable $ 50,826     $ 50,826     $ 34,966
Zai Lab | Interim Supply Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Amount on net product sales recognized   $ 9,500 $ 1,700 14,900 $ 2,500    
Zai Lab | Amended Zai Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
License revenue recognized 0   0 0 600    
Zai Lab | Manufacturing Stage Transfer Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
License revenue recognized 0   900 0 900    
Zai Lab | Regulatory Milestone Achievement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
License revenue recognized 4,000     4,000      
Zai Lab | Location, Statement of Financial Position, Balance [Axis]: us-gaap:AccountsReceivableNet | Interim Supply Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Accounts receivable 13,100     13,100     6,700
Zai Lab | Location, Statement of Financial Position, Balance [Axis]: us-gaap:AccountsReceivableNet | Amended Zai Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Accounts receivable 1,800     1,800     $ 1,800
Zai Lab | Research and Development Support | Maximum [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Future potential milestone payment receivable 91,000     91,000      
Zai Lab | Royalty Revenue              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Revenues 900   600 2,000 1,100    
Dr. Reddy's Laboratories              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
License revenue recognized 3,400     3,400      
GARDP Collaboration Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
License revenue recognized 2,000     2,000      
Research and development expense 0   0 0 0    
PAION AG | Maximum [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Future potential milestone payment receivable 109,500     109,500      
PAION AG | Cost Reimbursement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Revenues 1,800   800 1,800 1,400    
PAION AG | Royalty Revenue              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Revenues 800   0 $ 1,400 0    
Everest Medicines Limited              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Royalties payable period after first commercial sale of product       10 years      
Everest Medicines Limited | Maximum [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales milestone payments receivable 20,000     $ 20,000      
Everest Medicines Limited | Commercial Supply Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Revenues 1,300   800 $ 1,300 1,800    
Percentage of reimbursed for direct and certain indirect manufacturing costs       110.00%      
Everest Medicines Limited | Royalty Revenue              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Revenues 900   2,000 $ 900 2,000    
George Washington University | GIAPREZA              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of royalty payable on net sales       6.00%      
Percentage of royalty on payments received from sublicensees       15.00%      
Royalty expense 1,400   1,100 $ 2,700 2,200    
Harvard University              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of royalty on payments received from sublicensees       20.00%      
Royalty expense 0   600 $ 0 700    
Harvard University | U.S.              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of royalty payable on net sales       5.00%      
Harvard University | Minimum [Member] | Non-US              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of royalty payable on net sales       4.50%      
Harvard University | Maximum [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Clinical development and regulatory milestones amount payable       $ 15,100      
Harvard University | Maximum [Member] | Non-US              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Percentage of royalty payable on net sales       7.50%      
Basilea              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Upfront payment under intangible asset           $ 4,000  
Royalty expense 0     $ 0      
Astrazeneca | Durlobactam              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
One-time Milestone Payment on Net Sales       $ 5,000      
Term of the milestone payment on net sales       3 months      
Royalty expense 0   $ 0 $ 0 $ 0    
Astrazeneca | Zoliflodacin              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
One-time milestone payment on commercial sales       $ 10,000      
Term of milestone payment for commercial sale       2 years      
Massachusetts Institute of Technology              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Upfront fee payment       $ 500      
Massachusetts Institute of Technology | Development, Regulatory and Sales Milestone | Maximum [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Future potential milestone payable $ 17,500     $ 17,500